• 1
    Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) – classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy 2011;66:818829.
  • 2
    Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001;323:334336.
  • 3
    WHO. International drug monitoring: the role of national centers. WHO TRS 1972;498:125.
  • 4
    Kowalski ML, Demoly P, Pichler WJ, Sanchez-Borges M. Hypersensitivity to drugs and biological agents. In: Pawankar R, Canonica W, Holgate ST, Lockey RF, editors. WAO White Book on Allergy, Milwaukee: WAO, 2012: 5761.
  • 5
    Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM editor. Textbook of Adverse Drug Reactions. Oxford: Oxford University Press, 1977: 10.
  • 6
    Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol 2001;87:177180.
  • 7
    Caimmi S, Caimmi D, Bousquet PJ, Demoly P. How can we better classify NSAID hypersensitivity reactions? – validation from a large database. Int Arch Allergy Immunol 2012;159:306312.
  • 8
    Hedman J, Kaprio J, Poussa T. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999;28:717722.
  • 9
    Dona I, Blanca-Lopez N, Torres MJ, Garcia-Campos J, Garcia-Nunez I, Gomez F et al. Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. J Investig Allergol Clin Immunol 2012;22:363371.
  • 10
    Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004;328:434.
  • 11
    Kasper L, Sladek K, Duplaga M, Bochenek G, Liebhart J, Gladysz U et al. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy 2003;58:10641066.
  • 12
    Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000;16:432436.
  • 13
    Moore-Robinson M, Warin RP. Effect of salicylates in urticaria. Br Med J 1967;4:262264.
  • 14
    Doeglas HM. Reactions to aspirin and food additives in patients with chronic urticaria, including the physical urticarias. Br J Dermatol 1975;93:135144.
  • 15
    Dona I, Blanca-Lopez N, Cornejo-Garcia JA, Torres MJ, Laguna JJ, Fernandez J et al. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clin Exp Allergy 2011;41:8695.
  • 16
    Canto MG, Andreu I, Fernandez J, Blanca M. Selective immediate hypersensitivity reactions to NSAIDs. Curr Opin Allergy Clin Immunol 2009;9:293297.
  • 17
    Chaudhry T, Hissaria P, Wiese M, Heddle R, Kette F, Smith WB. Oral drug challenges in non-steroidal anti-inflammatory drug-induced urticaria, angioedema and anaphylaxis. Intern Med J 2012;42:665671.
  • 18
    Himly M, Jahn-Schmid B, Pittertschatscher K, Bohle B, Grubmayr K, Ferreira F et al. IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. J Allergy Clin Immunol 2003;111:882888.
  • 19
    Samter M, Beers RF Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 1968;68:975983.
  • 20
    Kowalski ML, Cieslak M, Perez-Novo CA, Makowska JS, Bachert C. Clinical and immunological determinants of severe/refractory asthma (SRA): association with Staphylococcal superantigen-specific IgE antibodies. Allergy 2011;66:3238.
  • 21
    Yoshimine F, Hasegawa T, Suzuki E, Terada M, Koya T, Kondoh A et al. Contribution of aspirin-intolerant asthma to near fatal asthma based on a questionnaire survey in Niigata Prefecture, Japan. Respirology 2005;10:477484.
  • 22
    Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J 1975;1:6769.
  • 23
    Szczeklik A. Prostaglandin E2 and aspirin-induced asthma. Lancet 1995;345:1056.
  • 24
    Szczeklik A, Nizankowska-Mogilnicka E, Sanak M. Hypersensitivity to aspirin and nonsteroidal anti-inflammatory drugs. In: Adkinson NF, Busse WW, Bochner BC, Holgate ST, Simons ER, Lemanske RF, editors. Middleton's Allergy, 7th edn. Mosby: Elsevier, 2009: 12271243.
  • 25
    Stevenson DD, Simon RA, Mathison DA, Christiansen SC. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol 2000;85:477482.
  • 26
    Szczeklik A, Sanak M. The broken balance in aspirin hypersensitivity. Eur J Pharmacol 2006;533:145155.
  • 27
    Wos M, Sanak M, Soja J, Olechnowicz H, Busse WW, Szczeklik A. The presence of rhinovirus in lower airways of patients with bronchial asthma. Am J Respir Crit Care Med 2008;177:10821089.
  • 28
    Shrestha PN, Kim SH, Jin HJ, Hwang EK, Nam YH, Park HS. Genetic mechanisms in aspirin-exacerbated respiratory disease. J Allergy (Cairo) 2012, doi: 10.1155/2012/794890.
  • 29
    Dursun AB, Woessner KA, Simon RA, Karasoy D, Stevenson DD. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Asthma Immunol 2008;100:420425.
  • 30
    Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczynska M, Picado C, Scadding G et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007;62:11111118.
  • 31
    Macy E, Bernstein JA, Castells MC, Gawchik SM, Lee TH, Settipane RA et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol 2007;98:172174.
  • 32
    Nizankowska E, Bestynska-Krypel A, Cmiel A, Szczeklik A. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 2000;15:863869.
  • 33
    Milewski M, Mastalerz L, Nizankowska E, Szczeklik A. Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol 1998;101:581586.
  • 34
    Bavbek S, Dursun AB, Birben E, Kalayci O, Misirligil Z. Cellular allergen stimulation test with acetylsalicylic acid-lysine is not a useful test to discriminate between asthmatic patients with and without acetylsalicylic acid sensitivity. Int Arch Allergy Immunol 2009;149:5864.
  • 35
    De Weck AL, Sanz ML, Gamboa PM, Aberer W, Blanca M, Correia S et al. Nonsteroidal anti-inflammatory drug hypersensitivity syndrome. A multicenter study. I. Clinical findings and in vitro diagnosis. J Investig Allergol Clin Immunol 2009;19:355369.
  • 36
    Kowalski ML, Ptasinska A, Jedrzejczak M, Bienkiewicz B, Cieslak M, Grzegorczyk J et al. Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest). Allergy 2005;60:11391145.
  • 37
    Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006;118:773786. quiz 787–78.
  • 38
    Gyllfors P, Bochenek G, Overholt J, Drupka D, Kumlin M, Sheller J et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 2003;111:11161121.
  • 39
    Dahlen SE, Malmstrom K, Nizankowska E, Dahlen B, Kuna P, Kowalski M et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:914.
  • 40
    Mastalerz L, Nizankowska E, Sanak M, Mejza F, Pierzchalska M, Bazan-Socha S et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest 2002;32:949955.
  • 41
    Awad OG, Lee JH, Fasano MB, Graham SM. Sinonasal outcomes after endoscopic sinus surgery in asthmatic patients with nasal polyps: a difference between aspirin-tolerant and aspirin-induced asthma? Laryngoscope 2008;118:12821286.
  • 42
    Kim JE, Kountakis SE. The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery. Ear Nose Throat J 2007;86:396399.
  • 43
    Stevenson DD, Pleskow WW, Simon RA, Mathison DA, Lumry WR, Schatz M et al. Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol 1984;73:500507.
  • 44
    Williams AN, Woessner KM. The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis. Curr Allergy Asthma Rep 2008;8:245252.
  • 45
    Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003;111:180186.
  • 46
    Szczeklik A, Nizankowska–Mogilnicka E, Sanak M. Hypersensitivity to aspirin and other NSAIDs. In: Kay AB, Bousquet J, Holt P, Kaplan A, editors. Allergy and Allergic Diseases, 2nd edn. Oxford, UK:Wiley-Blackwell, 2008: 19661979.
  • 47
    Asero R. Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria. J Allergy Clin Immunol 2003;111:10951098.
  • 48
    Kozel MM, Bossuyt PM, Mekkes JR, Bos JD. Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: a systematic review. J Am Acad Dermatol 2003;48:409416.
  • 49
    Mastalerz L, Setkowicz M, Sanak M, Szczeklik A. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol 2004;113:771775.
  • 50
    Dona I, Blanca-Lopez N, Jagemann LR, Torres MJ, Rondon C, Campo P et al. Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs. Allergy 2011;66:14281433.
  • 51
    Rubio M, Bousquet PJ, Gomes E, Romano A, Demoly P. Results of drug hypersensitivity evaluations in a large group of children and adults. Clin Exp Allergy 2012;42:123130.
  • 52
    Schubert B, Grosse Perdekamp MT, Pfeuffer P, Raith P, Brocker EB, Trautmann A. Nonsteroidal anti-inflammatory drug hypersensitivity: fable or reality? Eur J Dermatol 2005;15:1647.
  • 53
    Bavbek S, Ikinciogullari A, Dursun AB, Guloglu D, Arikan M, Elhan AH et al. Upregulation of CD63 or CD203c alone or in combination is not sensitive in the diagnosis of nonsteroidal anti-inflammatory drug intolerance. Int Arch Allergy Immunol 2009;150:261270.
  • 54
    Asero R. Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs. Clin Exp Allergy 2005;35:713716.
  • 55
    Zembowicz A, Mastalerz L, Setkowicz M, Radziszewski W, Szczeklik A. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol 2003;139:15771582.
  • 56
    Goksel O, Aydin O, Misirligil Z, Demirel YS, Bavbek S. Safety of meloxicam in patients with aspirin/non-steroidal anti-inflammatory drug-induced urticaria and angioedema. J Dermatol 2010;37:973979.
  • 57
    Asero R. Risk factors for acetaminophen and nimesulide intolerance in patients with NSAID-induced skin disorders. Ann Allergy Asthma Immunol 1999;82:554558.
  • 58
    Giavina-Bianchi P, Dente M, Giavina-Bianchi M, Mota AA, Kalil J. Codeine challenge in chronic urticaria patients. Allergol Immunopathol (Madr) 2007;35:280.
  • 59
    Asero R. Cetirizine premedication prevents acute urticaria induced by weak COX-1 inhibitors in multiple NSAID reactors. Eur Ann Allergy Clin Immunol 2010;42:174177.
  • 60
    Viola M, Rumi G, Valluzzi RL, Gaeta F, Caruso C, Romano A. Assessing potential determinants of positive provocation tests in subjects with NSAID hypersensitivity. Clin Exp Allergy 2010;41:96103.
  • 61
    Blanca-Lopez N, J Torres M, Dona I, Campo P, Rondon C, Seoane Reula ME et al. Value of the clinical history in the diagnosis of urticaria/angioedema induced by NSAIDs with cross-intolerance. Clin Exp Allergy 2013;43:8591.
  • 62
    Kowalski ML, Bienkiewicz B, Woszczek G, Iwaszkiewicz J, Poniatowska M. Diagnosis of pyrazolone drug sensitivity: clinical history versus skin testing and in vitro testing. Allergy Asthma Proc 1999;20:347352.
  • 63
    Rutkowski K, Nasser SM, Ewan PW. Paracetamol hypersensitivity: clinical features, mechanism and role of specific IgE. Int Arch Allergy Immunol 2012;159:6064.
  • 64
    Gomez E, Blanca-Lopez N, Torres MJ, Requena G, Rondon C, Canto G et al. Immunoglobulin E-mediated immediate allergic reactions to dipyrone: value of basophil activation test in the identification of patients. Clin Exp Allergy 2009;39:12171224.
  • 65
    Demoly P, Hillaire-Buys D. Classification and epidemiology of hypersensitivity drug reactions. Immunol Allergy Clin North Am 2004;24:345356, v.
  • 66
    Torres MJ, Mayorga C, Blanca M. Nonimmediate allergic reactions induced by drugs: pathogenesis and diagnostic tests. J Investig Allergol Clin Immunol 2009;19:8090.
  • 67
    Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:1519.
  • 68
    Gebhardt M, Wollina U. Cutaneous side-effects of nonsteroidal anti-inflammatory drugs (NSAID). Z Rheumatol 1995;54:405412.
  • 69
    Patel MR, Marfatia YS. Clinical study of cutaneous drug eruptions in 200 patients. Indian J Dermatol Venereol Leprol 2008;74:430.
  • 70
    Barbaud A. Contact dermatitis due to topical drugs. G Ital Dermatol Venereol 2009;144:527536.
  • 71
    Ward KE, Archambault R, Mersfelder TL. Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: a review of the literature. Am J Health Syst Pharm 2010;67:206213.
  • 72
    Mockenhaupt M, Kelly JP, Kaufman D, Stern RS. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol 2003;30:22342240.
  • 73
    Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JN, Naldi L et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007;157:989996.
  • 74
    Mihovilovic K, Ljubanovic D, Knotek M. Safe administration of celecoxib to a patient with repeated episodes of nephrotic syndrome induced by NSAIDs. Clin Drug Investig 2011;31:351355.
  • 75
    Mahboob A, Haroon TS. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol 1998;37:833838.
  • 76
    Foti C, Cassano N, Vena GA, Angelini G. Photodermatitis caused by oral ketoprofen: two case reports. Contact Dermatitis 2011;64:181183.
  • 77
    La Grenade L, Lee L, Weaver J, Bonnel R, Karwoski C, Governale L et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf 2005;28:917924.
  • 78
    Yesudian PD, Penny M, Azurdia RM, King CM. Ibuprofen-induced acute generalized exanthematous pustulosis. Int J Dermatol 2004;43:208210.
  • 79
    Makela L, Lammintausta K. Etoricoxib-induced acute generalized exanthematous pustulosis. Acta Derm Venereol 2008;88:200201.
  • 80
    Rozieres A, Vocanson M, Said BB, Nosbaum A, Nicolas JF. Role of T cells in nonimmediate allergic drug reactions. Curr Opin Allergy Clin Immunol 2009;9:305310.
  • 81
    Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003;139:683693.
  • 82
    Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology 2005;209:209216.
  • 83
    Barbaud A, Goncalo M, Bruynzeel D, Bircher A. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001;45:321328.
  • 84
    Holzle E, Neumann N, Hausen B, Przybilla B, Schauder S, Honigsmann H et al. Photopatch testing: the 5-year experience of the German, Austrian, and Swiss photopatch test group. J Am Acad Dermatol 1991;25:5968.
  • 85
    Macias E, Ruiz A, Moreno E, Laffond E, Davila I, Lorente F. Usefulness of intradermal test and patch test in the diagnosis of nonimmediate reactions to metamizol. Allergy 2007;62:14621464.
  • 86
    Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003;58:854863.
  • 87
    Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004;59:809820.
  • 88
    Rubio M, Bousquet PJ, Gomes E, Romano A, Demoly P. Results of drug hypersensitivity evaluations in a large group of children and adults. Clin Exp Allergy 2011;42:123130.
  • 89
    De Luca G, Verdoia M, Binda G, Schaffer A, Suryapranata H, Marino P. Aspirin desensitization in patients undergoing planned or urgent coronary stent implantation. A single-center experience. Int J Cardiol 2013;167:561563.
  • 90
    Grzelewska-Rzymowska I, Roznlecki J, Szmidt M. Aspirin “desensitization” in patients with aspirin-induced urticaria and angioedema. Allergol Immunopathol (Madr) 1988;16:305308.
  • 91
    Slowik SM, Slavin RG. Aspirin desensitization in a patient with aspirin sensitivity and chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2009;102:171172.
  • 92
    Simon RA. Prevention and treatment of reactions to NSAIDs. Clin Rev Allergy Immunol 2003;24:189198.
  • 93
    Pleskow WW, Stevenson DD, Mathison DA, Simon RA, Schatz M, Zeiger RS. Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol 1982;69:1119.
  • 94
    Berges-Gimeno MP, Simon RA, Stevenson DD. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2003;90:338341.
  • 95
    Stevenson DD, Hankammer MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol 1996;98:751758.
  • 96
    Rozsasi A, Polzehl D, Deutschle T, Smith E, Wiesmiller K, Riechelmann H et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy 2008;63:12281234.
  • 97
    Wong JT, Nagy CS, Krinzman SJ, Maclean JA, Bloch KJ. Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. J Allergy Clin Immunol 2000;105:9971001.
  • 98
    Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol 2005;95:509510.
  • 99
    Cortellini G, Testi S, Severino M, Chechi T, Iorno ML, Santucci A et al. Aspirin challenge/desensitisation before coronary stenting in subjects with history of hypersensitivity. A pragmatic approach. Eur Ann Allergy Clin Immunol 2012;44:160162.
  • 100
    Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2007;119:157164.
  • 101
    Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002;89:474478.